Entire Patent Family Reaching Approval in the United States

Uppsala, Sweden, December 19, 2024. The pharmaceutical company Dicot Pharma today announces that the United States Patent and Trademark Office (USPTO) has granted an additional patent for its erectile dysfunction drug candidate, LIB-01. The patent is part of a patent family now gaining full approval in the US with protection until 2042. This family is paramount in the company´s IP-work and significantly strengthens both product and method protection.

Dicot Pharma previously announced that the USPTO had issued a Notice of Allowance for three US patent applications within the same family. Two of these have now been granted, and the USPTO has confirmed that the third will be approved on December 24. With this, Dicot Pharma secures comprehensive protection in line with the original application.

One of the patents covers what is commonly referred to as "Composition of Matter," meaning it protects the active substance in LIB-01. This type of patent is considered particularly valuable for robust intellectual property protection.

The newly granted patents extend both product and method protections in the US until 2042. Dicot Pharma plans to file for corresponding patents in additional geographic regions worldwide.

For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: [email protected]

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot Pharma is listed on Nasdaq First North and has approximately 7,900 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.